Skip to content
Search

Latest Stories

Cipla chief offers clarity on Remdesivir supplies

By Amit Roy

ONE of the best informed on drugs for coronavirus is Yusuf Hamied, chairman of the Indian pharma giant Cipla, who expresses concern that the numbers in­fected in India are “going up and up”.


He says: “It has not yet peaked. Probably the peak will come in August, September.”

And his prognosis?

“I’m only hearing from sources in Amer­ica,” he replies. “Two months ago, it was suggested that up to two million Indians could die.”

Does he think that is a realistic assessment?

“No,” says Hamied, “because what no­body realised then is that although Indians are getting corona, the death rate is rela­tively low because of inbuilt immunity from earlier vaccinations.”

In a country of 1.3 billion, the official figures are that 723,185 people have had the virus. The death toll stands at 20,198, while 441,112 infected have recovered.

Hamied, who is currently at his London home, has disputed a story in the Guardian on June 30, headlined, “US secures world stock of key Covid-19 drug Remdesivir.”

It has caused widespread concern that if and when a vaccine becomes available, the US will again hoover up the world’s supply and leave nothing for others.

The report said: “No other country will be able to buy Remdesivir, which can help recovery from Covid-19, for the next three months at least.

“The US has bought up virtually all the stocks for the next three months of one of the two drugs proven to work against Covid-19, leaving none for the UK, Europe or most of the rest of the world.

“Experts and campaigners are alarmed both by the US uni­lateral action on Remdesivir and the wider implications, for in­stance in the event of a vaccine becoming available.

“The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.”

Hamied confirms that his company Cipla has been giv­en clear­ance to manufacture Remdesivir in India. He tells Eastern Eye: “I will tell you where the [Guardian] story was wrong. The drug Remdesivir was invented by Gilead, an American company. It was intended for use at the time of the Ebola epidemic in Africa, and there it didn’t do very well.

“When corona started, they tried it in America. It’s an antiviral drug. They say it was quite successful. So it has become the drug of choice because there is no com­plete remedy to corona. It is given by intra­venous injections. It’s like one of the many anti-viral drugs that we use in diseases such as HIV AIDs.”

He says of the 20-year patent on Remde­sivir, “invented 16 or 17 years ago, there are three years left (before the patent runs out)”.

Explaining the background of the engagement between Gilead and India, Hamied reveals: “Gilead about 10 years ago gave a number of Indian companies the right to produce some of their drugs in India, still under patent for HIV, called Tenofovir.

“Before expiry of the patent they gave us what they call a ‘voluntary licence’. That means you can go ahead and manufacture the drug. But you’re restricted to the coun­tries where you can sell the drug.”

Hamied goes on: “Then came hepatitis C. They developed the drug Sovaldi and again came to India and gave 10 Indian companies a voluntary licence for Sofosbu­vir and the freedom to market the drug at any price with a small royalty to Gilead.”

He tells the story of Remdesivir: “Again, they have come to India and given Indian companies the right to manufacture and market Remdesivir. They have given us a list of 130 countries where we are allowed to sell.”

He stresses: “It is totally free while the pandemic is on. The minute the pandemic ends they will want to re­negotiate the agreement. So they have been very fair, actually.”

This licence was given a few weeks ago. “They’ve given this to six compa­nies – Cipla, Hetero, Mylan, Cadila, Dr Reddy and Jubilant. We were an­ticipating this. So we did all the homework on Remdesivir.”

The Indian government has cleared two companies to make the drug for “emer­gency use” in India, one being Cipla. “We are manufacturing it in our Goa factory.”

Depending on demand, he reveals that his company could manufacture 30,000 in­jections a week and build up stocks, cur­rently at 400,000 injections, to between one and two million.

Hamied says: “The price in America today for a course of six injections is $2,500 (£1,990). And, in India, the average price is around $65 (£52) per injection. It’s in the market.”

Returning to the Guardian story, Hamied explains: “What the American government can do is only ask Gilead, ‘You first supply us.’ They can block export from America. But they can’t stop Cipla and other licensed companies from making it and supplying it wherever they wish. Our product, Cipremi, is not approved in America. We can only take an approved product there if it is US FDA approved.”

As to how good the drug is at helping coronavirus patients, Hamied emphasises: “It doesn’t cure but can give relief. If you don’t take the drug, you may be in hospital for 11 days. And if you take the drug, you’re in hospital eight days.”

He reveals the news from India is not that encouraging because doctors have found it has side effects, leading, for example, to liver problems. “So, instead of giving it for six days, they may reduce that to five.”

Hamied mentions two other drugs being used for coronavirus patients. “There is a drug of Roche which is under patent. The drug is called Actemra – the generic name is Tocilizuma. Cipla is the distributor of the drug. We don’t make it.

“There is a drug called Favipiravir. And this is an antiviral drug, a Japanese drug off patent. And the Japanese and the Chinese and the Russians have claimed that it is very good for corona. One company called Glenmark has got approval in India. Cipla is also making it and likely to get approval any day.”

Finally, on the search for a vaccine for the virus, Hamied says: “Our friends, the Poonawallas, who own the Serum Institute of India, are very optimistic and will be among the leaders to bring out a suitable vaccine for Covid-19.”

More For You

Radhakrishnan

Modi’s ruling coalition nominated Radhakrishnan, 68, who is the governor of the western state of Maharashtra, as its candidate for the post. (Photo credit: X/@narendramodi)

India elects BJP’s CP Radhakrishnan as vice president

INDIAN lawmakers elected CP Radhakrishnan, a former parliamentarian from Prime Minister Narendra Modi’s Bharatiya Janata Party (BJP), as the country’s new vice president on Tuesday. The election comes more than a month after the previous vice president resigned.

Jagdeep Dhankhar, whose term was to end in 2027, stepped down in July, citing health reasons.

Keep ReadingShow less
Peter Mandelson

Mandelson, 71, a veteran Labour politician and key figure in the party under former leader Tony Blair, had come under scrutiny after letters and emails to Epstein were published. (Photo: Getty Images)

Peter Mandelson removed as UK ambassador to US over Epstein links

PETER MANDELSON, the UK's ambassador to the United States, has been sacked over revelations about his friendship with the late sex offender Jeffrey Epstein, the government said.

"The Prime Minister has asked the Foreign Secretary to withdraw him as ambassador," a foreign ministry statement said, adding that new messages showed "the depth and extent of Peter Mandelson’s relationship with Jeffrey Epstein".

Keep ReadingShow less
High-stakes India–EU trade talks in New Delhi aim to break deadlock

European Commission president Ursula von der Leyen with Narendra Modi during a meeting in New Delhi in February

High-stakes India–EU trade talks in New Delhi aim to break deadlock

INDIA and the European Union are holding potentially decisive trade negotiations in New Delhi this week, seeking to resolve differences over agriculture, dairy and non-tariff barriers to meet an ambitious end of year deadline for a deal, Indian government and EU sources said.

New Delhi is seeking to deepen global partnerships after US president Donald Trump doubled tariffs on Indian goods to 50 per cent last month over India’s Russian oil purchases, hitting exports such as textiles, leather and chemicals.

Keep ReadingShow less
Charlie Kirk

Kirk co-founded Turning Point USA in 2012 at the age of 18, building it into the largest conservative youth organisation in the country. (Photo: Getty Images)

Trump ally Charlie Kirk shot dead: The key details

Highlights:

  • Conservative activist Charlie Kirk fatally shot at Utah Valley University
  • Shooter fired from a rooftop in what police called a “targeted attack”
  • Federal, state and local agencies involved in ongoing manhunt
  • Political leaders across parties condemn the killing

A MANHUNT was underway Thursday after conservative activist Charlie Kirk was fatally shot at Utah Valley University, an attack that has sparked concerns of rising political violence in the United States.

Keep ReadingShow less
Shabana Mahmood

Shabana Mahmood (Photo: Getty Images)

Calls grow for Shabana Mahmood to toughen settlement rules

HOME SECRETARY Shabana Mahmood is under pressure to immediately enforce stricter immigration rules as large numbers of migrants approach the point at which they can settle permanently in Britain.

Government figures revealed that from next year about 270,000 migrants will qualify for indefinite leave to remain (ILR), the legal right to stay in the UK. The number is expected to rise sharply, reaching more than 600,000 by 2028, reported the Times.

Keep ReadingShow less